

Giulio Cavalli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1786351/publications.pdf>

Version: 2024-02-01

128
papers

5,622
citations

109321

35
h-index

85541

71
g-index

132
all docs

132
docs citations

132
times ranked

8190
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 48-56.	0.9	71
2	Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e11-e11.	0.9	15
3	Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2022, 74, 654-664.	5.6	15
4	Myocarditis as a manifestation of Erdheim-Chester Disease: successful use of anti-IL1 and BRAF inhibitor combination therapy. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 243-245.	1.1	2
5	Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	1
6	Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation. <i>Rheumatology</i> , 2022, 61, 4409-4419.	1.9	10
7	Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series. <i>Arthritis and Rheumatology</i> , 2022, 74, 1302-1303.	5.6	21
8	Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. <i>RMD Open</i> , 2022, 8, e002170.	3.8	32
9	Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. <i>RMD Open</i> , 2022, 8, e002168.	3.8	35
10	Retention rate of IL-1 inhibitors in Schnitzler's syndrome.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
11	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
12	Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. <i>RMD Open</i> , 2022, 8, e002167.	3.8	28
13	Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e143-e146.	0.9	13
14	Anakinra in COVID-19: How to Interpret Elevations of Serum Liver Enzymes: Comment on the Article by Navarro-Millán et al. <i>Arthritis and Rheumatology</i> , 2021, 73, 549-549.	5.6	0
15	Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , 2021, 133, 104071.	2.5	49
16	A Novel Histiocytosis With Synovial and Skin Involvement. <i>Annals of Internal Medicine</i> , 2021, 174, 273-274.	3.9	2
17	Drug retention rates of biological agents in adult onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1-6.	3.4	14
18	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab015.	0.7	5

#	ARTICLE	IF	CITATIONS
19	Canakinumab injection for the treatment of active Stillâ€™s disease, including adult-onset Stillâ€™s disease. Expert Opinion on Orphan Drugs, 2021, 9, 77-86.	0.8	1
20	The choice of early treatment and the impact of future relapses in adult onset Stillâ€™s disease. Rheumatology, 2021, 60, 2500-2501.	1.9	0
21	The right place for IL-1 inhibition in COVID-19. Lancet Respiratory Medicine, the, 2021, 9, 223-224.	10.7	39
22	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. Frontiers in Immunology, 2021, 12, 653950.	4.8	26
23	Interleukin 1 \pm : a comprehensive review on the role of IL-1 \pm in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmunity Reviews, 2021, 20, 102763.	5.8	140
24	Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.. European Journal of Internal Medicine, 2021, 86, 34-40.	2.2	61
25	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatology, The, 2021, 3, e253-e261.	3.9	140
26	The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity. Cell Reports, 2021, 35, 108955.	6.4	40
27	POS1347â€™...IMPACT OF CANAKINUMAB AND ANAKINRA ON PATIENT-REPORTED OUTCOMES IN ADULT-ONSET STILLâ€™S DISEASE PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 955.3-956.	0.9	0
28	POS0370â€™...TYPE I INTERFERON PATHWAY ASSAYS IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES - SYSTEMATIC LITERATURE REVIEW (SLR) AND DEVELOPMENT OF CONSENSUS TERMINOLOGY FROM A EULAR TASKFORCE. Annals of the Rheumatic Diseases, 2021, 80, 415-415.	0.9	0
29	Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses. Genome Medicine, 2021, 13, 94.	8.2	5
30	POS1336â€™...RETROPERITONEAL FIBROSIS IN ERDHEIM-CHESTER DISEASE HAS UNIQUE PRESENTING AND PROGNOSTIC FEATURES: A SINGLE CENTRE RETROSPECTIVE COMPARATIVE COHORT STUDY. Annals of the Rheumatic Diseases, 2021, 80, 950-951.	0.9	0
31	POS1341â€™...TOCILIZUMAB FOR THE TREATMENT OF IMMUNE-RELATED ADVERSE EVENTS TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES. Annals of the Rheumatic Diseases, 2021, 80, 953.1-953.	0.9	2
32	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. Blood, 2021, 138, 1554-1569.	1.4	10
33	Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis. Nature Communications, 2021, 12, 4559.	12.8	17
34	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine, 2021, 27, 1752-1760.	30.7	353
35	In the limelight: AA amyloidosis exposes TNF receptor-1 associated periodic syndrome. Rheumatology, 2021, 60, 5493-5494.	1.9	1
36	A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM). Frontiers in Medicine, 2021, 8, 723506.	2.6	10

#	ARTICLE	IF	CITATIONS
37	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology</i> , The, 2021, 3, e690-e697.	3.9	121
38	The course of action for effective anti-cytokine treatment in COVID-19. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 1353-1354.	10.7	4
39	Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. <i>Rheumatology</i> , 2020, 59, 171-175.	1.9	23
40	Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. <i>Journal of Rheumatology</i> , 2020, 47, 1780-1784.	2.0	9
41	Current treatment options and safety considerations when treating adult-onset Still's disease. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1549-1558.	2.4	15
42	Autophagy in the regulation of protein secretion in immune cells. , 2020, , 141-173.		0
43	Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness. <i>European Journal of Internal Medicine</i> , 2020, 82, 23-24.	2.2	1
44	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e325-e331.	3.9	808
45	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 42.	2.6	21
46	Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 536-544.	0.9	44
47	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1277-1285.	0.9	212
48	Erdheim-Chester disease: An in vivo human model of M ϕ activation at the crossroad between chronic inflammation and cancer. <i>Journal of Leukocyte Biology</i> , 2020, 108, 591-599.	3.3	9
49	Autophagy and Protein Secretion. <i>Journal of Molecular Biology</i> , 2020, 432, 2525-2545.	4.2	53
50	Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 509-514.	3.4	24
51	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020, 76, 43-49.	2.2	349
52	FRI0506...EFFICACY AND SAFETY OF CANAKINUMAB IN ADULT-ONSET STILL'S DISEASE: A SINGLE-CENTER REAL-LIFE EXPERIENCE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851.1-852.	0.9	43
53	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020, 11, 598308.	3.5	29
54	FRI0484...SAFETY PROFILE, CLINICAL AND RADIOLOGICAL EFFICACY OF ANAKINRA, TARGETED AND COMBINED TREATMENT IN ERDHEIM-CHESTER DISEASE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 839.1-840.	0.9	0

#	ARTICLE	IF	CITATIONS
55	SAT0519â€¦DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILLâ€™S DISEASE IN THE PRE-CANAKINUMAB ERA. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1215-1216.	0.9	0
56	Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1313-1322.	3.0	10
57	168.â€fGENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
58	Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 482-490.	1.1	22
59	Long-Term Retention Rate of Anakinra in Adult Onset Stillâ€™s Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	3.5	35
60	Efficacy of canakinumab as first-line biologic agent in adult-onset Stillâ€™s disease. <i>Arthritis Research and Therapy</i> , 2019, 21, 54.	3.5	31
61	P087â€¦The anti-inflammatory cytokine interleukin 37 is an endogenous inhibitor of trained immunity. , 2019, , .		0
62	P105â€¦Identification of rare coding variants in IL-1-related pathways in patients with adult-onset stillâ€™s disease. , 2019, , .		0
63	AB0621â€¦.GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS. , 2019, , .		2
64	THU0570â€¦EFFICACY AND SAFETY OF ANAKINRA IN THE TREATMENT OF AUTOIMMUNE MYOCARDITIS. , 2019, , .		0
65	Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance. <i>Journal of Clinical Rheumatology</i> , 2019, Publish Ahead of Print, .	0.9	7
66	3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 862-864.	0.9	8
67	Prevalence of Takayasu arteritis in young women with acute ischemic heart disease. <i>International Journal of Cardiology</i> , 2018, 252, 21-23.	1.7	19
68	Suppression of inflammation and acquired immunity by <scp>IL</scp>â€37. <i>Immunological Reviews</i> , 2018, 281, 179-190.	6.0	225
69	Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheimâ€™Chester disease. <i>Journal of Neurology</i> , 2018, 265, 273-284.	3.6	17
70	Publications Are Not the Finish Line: Focusing on Societal Rather Than Publication Impact. <i>Frontiers in Medicine</i> , 2018, 5, 314.	2.6	7
71	Anakinra Therapy for Non-cancer Inflammatory Diseases. <i>Frontiers in Pharmacology</i> , 2018, 9, 1157.	3.5	198
72	Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. <i>Annals of Internal Medicine</i> , 2018, 169, 819.	3.9	34

#	ARTICLE	IF	CITATIONS
73	Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. <i>European Journal of Internal Medicine</i> , 2018, 57, e11-e12.	2.2	36
74	Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1233.	4.8	37
75	Myocarditis: An Interleukin-1-Mediated Disease?. <i>Frontiers in Immunology</i> , 2018, 9, 1335.	4.8	53
76	Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. <i>Journal of Biological Chemistry</i> , 2018, 293, 14224-14236.	3.4	42
77	Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2018, 25, 1.	0.9	2
78	Letter by Campochiaro et al Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity". <i>Circulation</i> , 2018, 137, 2421-2422.	1.6	3
79	The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. <i>Oncolmmunology</i> , 2018, 7, e1440929.	4.6	17
80	Cardiovascular disease in patients with rheumatoid arthritis: impact of classic and disease-specific risk factors. <i>Annals of Translational Medicine</i> , 2018, 6, S82-S82.	1.7	7
81	Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it?. <i>European Review for Medical and Pharmacological Sciences</i> , 2018, 22, 2189-2190.	0.7	2
82	AB1159...Virus-negative lymphocytic myocarditis: clinical and diagnostic features from a monocentric italian cohort. , 2018, , .		0
83	AB1135...Cardiac magnetic resonance findings in patients with biopsy-proven virus-negative lymphocytic myocarditis. , 2018, , .		0
84	Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2313-2318.	7.1	87
85	QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. <i>International Journal of Cardiology</i> , 2017, 239, 33.	1.7	18
86	SMAD4 gene mutation and risk of aortic dilation: Lessons from hereditary hemorrhagic telangiectasia. <i>International Journal of Cardiology</i> , 2017, 245, 145-146.	1.7	3
87	Priorities of biomedical research. <i>International Journal of Cardiology</i> , 2017, 245, 256.	1.7	4
88	OP0092...Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration and improves exercise tolerance. , 2017, , .		1
89	Tocilizumab in patients with multisystem Erdheim-Chester disease. <i>Oncolmmunology</i> , 2017, 6, e1318237.	4.6	29
90	FRI0325...Prevalence of takayasu arteritis in young women with acute ischemic heart disease. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
91	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 369.	3.5	89
92	Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure. <i>Frontiers in Immunology</i> , 2017, 8, 131.	4.8	53
93	Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera. <i>Medicine (United States)</i> , 2016, 95, e3697.	1.0	8
94	Treating Life-Threatening Myocarditis by Blocking Interleukin-1*. <i>Critical Care Medicine</i> , 2016, 44, e751-e754.	0.9	75
95	Hypertrophic cardiomyopathy secondary to hepatitis C virus-related vasculitis. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e156-e157.	1.5	2
96	FR1001...Treating Experimental Arthritis with The Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 426.1-426.	0.9	0
97	Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. <i>Rheumatology</i> , 2016, 55, 2220-2229.	1.9	77
98	Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. <i>Oncotarget</i> , 2016, 5, e1181244.	4.6	14
99	MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1363-1368.	7.1	88
100	Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1357-1362.	7.1	46
101	Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case. <i>Modern Rheumatology</i> , 2016, 26, 276-277.	1.8	5
102	An enlightening scan. <i>European Journal of Internal Medicine</i> , 2015, 26, 68-69.	2.2	1
103	Efficacy and safety of biological agents in adult-onset Still's disease. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 309-314.	1.1	66
104	Treating Pulmonary Silicosis by Blocking Interleukin 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 596-598.	5.6	48
105	Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 48-54.	3.4	75
106	Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. <i>Rheumatology</i> , 2015, 54, kev269.	1.9	91
107	Erdheim-Chester disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 223-229.	2.2	123
108	Orthopnea with platydeoxia secondary to prominent Eustachian valve. <i>Intensive Care Medicine</i> , 2015, 41, 918-919.	8.2	2

#	ARTICLE	IF	CITATIONS
109	Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity. <i>Autoimmunity Reviews</i> , 2015, 14, 352-357.	5.8	44
110	BRAF ^{V600E} -mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1596-1602.	0.9	94
111	Oncogene-Induced Senescence as a New Mechanism of Disease: The Paradigm of Erdheim-Chester Disease. <i>Frontiers in Immunology</i> , 2014, 5, 281.	4.8	40
112	Aortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2014, 166, 470-470.	2.5	2
113	A Bitter Effect: Thrombocytopenia Induced by a Quinidine-containing Beverage. <i>American Journal of Medicine</i> , 2014, 127, e1-e2.	1.5	4
114	Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 483-492.	1.4	462
115	THU0372...The Role of Echocardiography and Cardiac MRI in Erdheim-Chester Disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 311.1-311.	0.9	0
116	Charcot's arthropathy of the spine. <i>Arthritis and Rheumatism</i> , 2013, 65, 342-342.	6.7	5
117	The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1691-1695.	0.9	163
118	Diagnosing Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, e19-e19.	0.9	10
119	Charcot's Arthropathy of the Hip. <i>Journal of Rheumatology</i> , 2013, 40, 1770-1770.	2.0	3
120	AB0742...Pure peripheral giant cell arteritis: A systematic literature review of a poorly characterized clinical entity. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 681.2-681.	0.9	0
121	AB0746...Juvenile temporal arteritis: Report of a case and review of the literature. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 681.6-681.	0.9	0
122	THU0386...Efficacy of long-term treatment with biologic agents in refractory adult onset still's disease: A single centre experience on 16 patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 286.1-286.	0.9	0
123	FRI0486...Cardiac cine mri in erdheim-chester disease: data from a large italian cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A539.2-A539.	0.9	0
124	THU0209...Efficacy of anti-TNF therapy in 15 patients with refractory takayasu's arteritis: Long term unicentric follow-up. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 226.1-226.	0.9	5
125	THU0373...Clinical presentation of erdheim-chester disease: Data from a cohort of 10 patients and review of the literature. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 281.3-282.	0.9	0
126	Advances in potential targeted therapies for Erdheim-Chester disease. <i>Expert Opinion on Orphan Drugs</i> , 0, 1-8.	0.8	5

#	ARTICLE	IF	CITATIONS
127	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. Clinical and Experimental Rheumatology, 0, , .	0.8	3
128	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. Clinical and Experimental Rheumatology, 0, , .	0.8	1